Corcept Therapeutics (CORT) Q4 Earnings and Revenues Miss Estimates

Core Insights - Corcept Therapeutics reported quarterly earnings of $0.26 per share, missing the Zacks Consensus Estimate of $0.37 per share, and showing a decrease from $0.28 per share a year ago, resulting in an earnings surprise of -29.73% [1] - The company posted revenues of $181.89 million for the quarter ended December 2024, which was 7.08% below the Zacks Consensus Estimate, but an increase from $135.41 million year-over-year [2] - Corcept has surpassed consensus EPS estimates three times over the last four quarters, indicating a mixed trend in estimate revisions ahead of the earnings release [2][6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.39 on revenues of $189.08 million, and for the current fiscal year, it is $1.85 on revenues of $811.91 million [7] - The stock has outperformed the S&P 500, gaining about 21.5% since the beginning of the year compared to the S&P 500's gain of 1.3% [3] - The Zacks Industry Rank for Medical - Drugs is in the top 50% of over 250 Zacks industries, suggesting that the industry outlook can significantly impact stock performance [8] Industry Context - Recursion Pharmaceuticals, another company in the same industry, is expected to report a quarterly loss of $0.36 per share, with revenues projected at $28.73 million, reflecting a year-over-year increase of 163.9% [9][10]